信号识别颗粒受体β子单元促进心脏衰竭小鼠的心律失常性重塑
Jingjing Zhang1,2,3, Yucheng Pan1,2,3, Yang Gong1,2,3
1Department of Cardiology Renmin Hospital of Wuhan University Wuhan Hubei People's Republic of China.
Journal of the American Heart Association
|January 22, 2026
概括
减少信号识别粒子受体β子单元 (Srprb) 通过减少心室失常症,改善了小鼠心力衰竭的结果. 相反,增加Srprb加剧了心力衰竭和心律失常的增加,突出了Srprb作为治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 分子心脏病学分子心脏病学
- 细胞内膜网膜应激压力
背景情况:
- 心力衰竭 (HF) 是全球主要的死亡原因,常常由心室失常症 (VAs) 复杂化.
- 信号识别粒子受体β子单元 (Srprb) 是一种内细胞网膜中的蛋白质,参与蛋白质加工.
研究的目的:
- 在心力衰竭的小鼠模型中调查Srprb在心脏重塑和VA易感性中的作用.
主要方法:
- 用小鼠的腺相关病毒实现了对心脏特异性的Srprb过度表达或淘汰.
- 一个压力过载诱导的心力衰竭模型是通过大动脉带带创建的.
- 评估了心脏功能,电生理学和分子变化,以及对心肌细胞和纤维细胞的体外研究.
主要成果:
- Srprb knockdown 改善了心脏结构和电力改造,减少了压力过载引起的心力衰竭的静脉血管.
- 过度表达Srprb加剧了改造和增加了VA发病率.
- 在体外,Srprb调制影响了心肌细胞缩和纤维细胞纤维化,其介导由内质网膜应激和TLR4/CaMKII/NF-κB通路.
结论:
- 抗心脏衰竭的Srprb knockdown可以防止心室重塑和心力衰竭中的心律失常.
- 过度表达Srprb会加剧心力衰竭表型并增加VA风险.
- 向Srprb可能为管理心力衰竭并发症提供一种新的治疗策略.
相关概念视频
01:29Heart Failure II: Pathophysiology
790
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
790
02:54Nucleosome Remodeling
10.8K
Nucleosomes are the basic units of chromatin compaction. Each nucleosome consists of the DNA bound tightly around a histone core, which makes the DNA inaccessible to DNA binding proteins such as DNA polymerase and RNA polymerase. Hence, the fundamental problem is to ensure access to DNA when appropriate, despite the compact and protective chromatin structure.
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
10.8K
01:17Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
01:27Heart Failure I: Introduction
729
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
729
01:21G-protein Coupled Receptors
131.7K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
131.7K
01:22Heart Failure VI: Adjunct Therapies
278
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
278